Compare Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares) (ITUB) vs Kymera Therapeutics Inc. Common Stock (KYMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares) vs Kymera Therapeutics Inc. Common Stock — how do they compare? Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares) trades at $9.45 (market cap $114.26B), while Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.88B). The key difference: Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares) is far larger — about 12.9× Kymera Therapeutics Inc. Common Stock's market cap, and Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares) pays a 1.73% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares) for 3 Days and Kymera Therapeutics Inc. Common Stock for 0 Days on average.
| ITUB | KYMR | |
|---|---|---|
Market Cap | $114.26B | $8.88B |
Volume | 41,905,072 | 1,028,790 |
Sector | Financials | Health |
52-Week High | $10.16 | $127.31 |
52-Week Low | $6.86 | $55.80 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $1.34T | $8.27B |
Dividend Yield | 1.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ITUB trades at $9.89, down 1.69% today, following recent profit-taking after reaching 52-week highs. The stock shows bullish technical momentum with strong moving average signals, though RSI indicates overbought conditions. Fundamentally, the bank maintains robust profitability with 27.65% net margin and 21.97% ROE, though recent quarters have seen earnings misses. The company recently received preliminary US bank charter approval, expanding its wealth management services for Latin American clients.
Outlook remains cautiously optimistic with analyst consensus at Buy (46%) and price target of $9.80. Key opportunities include US expansion and strong Brazilian market position, while risks include Brazil's high risk-free rate, competitive pressures, and earnings consistency concerns. The stock trades near fair value with P/E of 11.75 and P/B of 2.5.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares)
Itaú Unibanco is a Brazilian financial services company providing banking, credit, insurance, and investment products. It serves individual, business, and corporate clients.
Read more on ITUB →About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →
